Compare NTHI & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTHI | MGYR |
|---|---|---|
| Founded | 2008 | 1922 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 123.3M |
| IPO Year | 2023 | 2021 |
| Metric | NTHI | MGYR |
|---|---|---|
| Price | $3.35 | $19.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 179.9K | 1.3K |
| Earning Date | 05-19-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.30% |
| EPS Growth | N/A | ★ 26.83 |
| EPS | N/A | ★ 1.47 |
| Revenue | ★ $39,990.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.17 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $16.03 |
| 52 Week High | $12.99 | $20.00 |
| Indicator | NTHI | MGYR |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 50.87 |
| Support Level | $3.03 | $16.95 |
| Resistance Level | $3.70 | $19.89 |
| Average True Range (ATR) | 0.42 | 0.31 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 15.74 | 38.00 |
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.